Transfusion‐transmitted CMV infection – current knowledge and future perspectives. Issue 4 (23rd June 2017)

• Record Type: Journal Article
• Authors: Ziemann, M.; Thiele, T.
• Is Part Of: Transfusion medicine. Volume 27:Issue 4(2017:Aug.)
• Page Start: 238
• Page End: 248
• Publication Date: 2017-06-23
• Subjects: CMV testing -- cytomegalovirus -- transfusion‐transmitted CMV infection; Blood -- Transfusion -- Periodicals; 615.39
• DOI: 10.1111/tme.12437
• Languages: English
• ISSNs: 0958-7578

Abstract

SUMMARY: Transmission of human cytomegalovirus (CMV) via transfusion (TT‐CMV) may still occur and remains a challenge in the treatment of immunocompromised CMV‐seronegative patients, e.g. after stem cell transplantation, and for low birthweight infants. Measures to reduce the risk of TT‐CMV have been evaluated in clinical studies, including leucocyte depletion of cellular blood products and/or the selection of CMV‐IgG‐negative donations. Studies in large blood donor cohorts indicate that donations from newly CMV‐IgG‐positive donors should bear the highest risk for transmitting CMV infections because they contain the highest levels of CMV‐DNA, and early CMV antibodies cannot neutralise CMV. Based on this knowledge, rational strategies to reduce the residual risk of TT‐CMV using leucoreduced blood products could be designed. However, there is a lack of evidence that CMV is still transmitted by transfusion of leucoreduced units. In low birthweight infants, most (if not all) CMV infections are caused by breast milk feeding or congenital transmission rather than by transfusion of leucoreduced blood products. For other patients at risk, no definitive data exist about the relative importance of alternative transmission routes of CMV compared to blood transfusion. As a result, only the conduction of well‐designed studies addressing strategies to prevent TT‐CMV and the thorough examination of presumed cases of TT‐CMV will achieve guidance for the best transfusion regimen in patients at risk.